Glaxo receives FDA 'complete response' for cervical cancer vaccine
Dec 17 2007 - 8:24am
GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX
Share this content.
Contact Us To Be Mentioned in EmaxHealth.com